Lenalidomide-induced cytopenias: Relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS)

被引：2
|
作者：
Sekeres, Mikkael A. [1 ]
Maciejewski, Jwoslaw P. [1 ]
Giagounidis, Aristoteles [2 ]
Wride, Kenton [3 ]
Knight, Robert D. [3 ]
Raza, Azra [4 ]
List, Alan F. [5 ]
机构：
[1] Cleveland Clin Taussig Canc, Cleveland, OH USA
[2] St Johannes Hosp, Duisburg, Germany
[3] Celgene Corp, Summit, NJ USA
[4] Univ Massachusetts, Med Ctr, Worcester, MA 01003 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.821.821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
821
引用
收藏
页码：252A / 252A
页数：1
相关论文
共 50 条
  • [1] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104
  • [2] Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Giagounidis, Aristotle A. N.
    Wride, Kenton
    Knight, Robert
    Raza, Azra
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5943 - 5949
  • [3] Arsenic trioxide (Trisenox®) with/without thalidomide in patients with myelodysplastic syndromes (MDS) produces hematologic improvement (HI).
    Raza, A
    Lisak, L
    Billmeier, J
    Akbar, S
    Washeed, K
    Mumtaz, M
    Reddy, P
    Galili, N
    BLOOD, 2004, 104 (11) : 261B - 262B
  • [4] Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Qawi, H
    Naseer, OB
    Dar, S
    Lisak, L
    Andric, T
    Ali, SI
    Quadri, M
    Ahmed, B
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    BLOOD, 1998, 92 (10) : 631A - 631A
  • [5] Hematologic improvement in response to anti-tumor necrosis factor (TNF) therapy with Remicade® in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, LA
    Tahir, S
    Billmeier, JM
    Willmann, HS
    Bellak, DJ
    Alvi, MI
    Gezer, S
    Venugopal, P
    BLOOD, 2002, 100 (11) : 795A - 795A
  • [6] Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes
    DeZern, Amy E.
    Binder, Gary
    Fliss, Albert
    Hu, X. Henry
    Rizvi, Syed
    Corvino, Frank A.
    Arikian, Steven R.
    Surinach, Andy
    Lee, Jianyi
    Smith, B. Douglas
    BLOOD, 2015, 126 (23)
  • [7] Pregnancy in patients with myelodysplastic syndromes (MDS)
    Volpicelli, P.
    Latagliata, R.
    Breccia, M.
    Carmosino, I.
    Stefanizzi, C.
    Iannella, E.
    Levi, A.
    Natalino, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2007, 31 : S107 - S107
  • [8] Pregnancy in patients with myelodysplastic syndromes (MDS)
    Volpicelli, P.
    Latagliata, R.
    Breccia, M.
    Carmosino, I.
    Stefanizzi, C.
    Napoleone, L.
    Vozella, F.
    Levi, A.
    Natalino, E.
    Alimena, G.
    LEUKEMIA RESEARCH, 2008, 32 (10) : 1605 - 1607
  • [9] Lenalidomide treatment and the effects on T-cell receptor repertoire in patients with myelodysplastic syndromes (MDS)
    Momot, T.
    Koenig, J.
    Ganser, A.
    Mischak-Weissinger, E.-M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 413 - 414
  • [10] T-cell receptor repertoire in patients with myelodysplastic syndromes (MDS) receiving lenalidomide treatment
    Momot, T.
    Koenig, J.
    Ganser, A.
    Weissinger, E.-M.
    LEUKEMIA RESEARCH, 2007, 31 : S65 - S65
12345